Pharmacological Blockade of LPAR1 Does Not Provide Neuroprotection in a Rat Model of Ocular Hypertensive Glaucoma
Our study provides evidence that pharmacological targeting of LPAR1 as a potential therapeutic avenue in glaucoma may not be beneficial.
Authors
- Sai Kocherlakota (ORCID: https://orcid.org/0000-0002-2488-2832)
- James R. Tribble (ORCID: https://orcid.org/0000-0001-8301-7358)
- Paul Williams (ORCID: https://orcid.org/0000-0002-1920-5036)
- Karin J. Stebbins
- Filippo Locri (ORCID: https://orcid.org/0009-0000-3772-8730)
- Alan Nicol
- Daniel S. Lorrain
Institutions
- Karolinska Institutet (SE)
- Centre for Eye Research Australia (AU)
- S:t Eriks Ögonsjukhus (SE)
- Optimum Therapeutics (United States) (US)
Publication Details
- Journal
- Translational Vision Science & Technology
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1167/tvst.15.1.11
- Primary Topic
- Glaucoma and retinal disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Karolinska Institutet
- Vetenskapsrådet
- S:t Eriks Ögonforskningsstiftelse